Related Experiment Video
Updated: Jun 9, 2025

10:10
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
Published on: October 18, 2011
12.6K
Cognitive dysfunction induced by cranial radiotherapy: mechanisms and therapeutic methods.
1Department of Radiology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China.
Brain Research Bulletin
|October 24, 2024
Summary
Cranial radiotherapy can cause cognitive dysfunction by damaging brain tissues. This review explores mechanisms and therapeutic advances for radiotherapy-induced brain injury, including neuroprotection and drug delivery systems.
Area of Science:
- Neuroscience
- Oncology
- Radiology
Background:
- Cranial radiotherapy can lead to cognitive dysfunction due to damage to normal brain tissues.
- This dysfunction is linked to hippocampal injury, white matter damage, and microvascular injury.
Purpose of the Study:
- To review the mechanisms of cognitive dysfunction induced by cranial radiotherapy and combined chemoradiotherapy.
- To summarize advances in therapeutic methods for radiotherapy-induced brain injury.
Main Methods:
- Literature review of mechanisms of radiotherapy-induced brain injury.
- Summary of current and future therapeutic strategies.
Main Results:
- Mechanisms include impaired neurogenesis, neuronal and glial cell damage, vascular injury, oxidative stress, DNA damage, cell death, and inflammation.
- Blood-brain barrier disruption exacerbates damage.
- Current prevention methods include precision radiotherapy, stem cell transplantation, and neuroprotective drugs.
Conclusions:
- Combined precision radiotherapy and neuroprotective drugs may offer enhanced neuroprotection.
- Future strategies involve nanoenzymes and drug delivery nano-systems to overcome blood-brain barrier challenges.
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
101
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
101
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165

